Exhibit 99.1

ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2018

Revenue increased 13% to $523.7 million; up 11% on a constant currency basis

GAAP diluted earnings per share of $0.60; non-GAAP diluted earnings per share of $0.66

Operating cash flow of $94.0 million in the first quarter

SAN DIEGO, October 26, 2017 – ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended September 30, 2017. Revenue for the quarter was $523.7 million, a 13 percent increase compared to the same period of the prior year.

“We started the fiscal year with strong 11 percent constant currency revenue growth led by our masks, software-as-a-service solutions, and devices,” said Mick Farrell, ResMed’s chief executive officer. “Our new masks have performed well around the world, device sales are solid, and operating profit returned to double-digit growth in the quarter.”

Farrell concluded, “We are achieving share gains with new product innovation and delivering sustainable operating profit growth. We continue to pioneer products, services and solutions that improve patient outcomes, create efficiencies for our homecare providers, and help physicians and payers better manage chronic disease and lower long-term healthcare costs.”

Analysis of first quarter results

First quarter revenue in the Americas, excluding Brightree, was $296.6 million, an 11 percent increase over the same period of the prior year. Brightree revenue for the first quarter was $38.1 million, an increase of 15 percent compared to the same period of the prior year. Revenue in combined EMEA and APAC was $189.0 million, an increase of 11 percent on a constant currency basis, compared to the same period of the prior year.

Gross margin in the first quarter was 58.4 percent, higher than the prior year’s quarter gross margin of 57.8 percent. The improvement in gross margin compared to prior year was due to manufacturing and procurement efficiencies and the prior year Astral field safety notification expenses, which were partially offset by declines in average selling prices.

Income from operations for the quarter was $112.6 million, a 20 percent increase compared with the quarter ended September 30, 2016. Non-GAAP income from operations for the quarter was $124.3 million, a 12 percent increase compared to the same period of the prior year.

Selling, general and administrative expenses were $143.9 million, a 12 percent increase over the same period in the prior year, or a 10 percent increase on a constant currency basis. SG&A expenses improved to 27.5 percent of revenue in the quarter, compared with 27.7 percent reported in the quarter ended September 30, 2016.    

Research and development expenses were $37.4 million, or 7.1 percent of revenue. R&D expenses increased by 9 percent compared with the same period last year, or a 6 percent increase on a constant currency basis.

Amortization of acquired intangible assets was $11.8 million during the quarter, which is consistent with the same period last year. Stock-based compensation costs incurred during the quarter of $11.9 million consisted of expenses associated with employee equity grants, and our employee stock purchase plan.

Net income for the quarter was $86.1 million, a 13 percent increase compared to the same period of the prior year. Non-GAAP net income was $94.1 million, a 7 percent increase compared to the prior year.

Non-GAAP measures adjust for amortization of acquired intangibles and the Astral battery field safety notification expenses.

GAAP diluted earnings per share for the quarter increased by 11 percent to $0.60. Non-GAAP diluted earnings per share of $0.66 were 6 percent higher compared with the same period of the prior year.

Cash flow from operations for the quarter was $94.0 million compared to net income in the current quarter of $86.1 million. During the quarter we paid $49.7 million in dividends and repaid $60.0 million of our outstanding debt.

Dividend program

The ResMed board of directors today declared a quarterly cash dividend of $0.35 per share. The dividend will have a record date of November 9, 2017, payable on December 14, 2017. The dividend will be paid in U.S. currency to holders of ResMed’s common stock trading on the New York Stock Exchange. Holders of Chess Depositary Instruments trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be November 8, 2017 for common stock holders and for CDI holders. ResMed has received a waiver from the ASX’s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from November 8, 2017 through November 9, 2017 inclusive.

Webcast details

ResMed will discuss its first quarter fiscal year 2018 results on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on ResMed’s Investor Relations website at investor.resmed.com. Please go to this section of the website and click on the icon for the “Q1 2018 earnings webcast” to register and listen to the live webcast. A replay of the earnings webcast will be accessible on our website and available approximately two hours after the live webcast. In addition, a telephone replay of the conference call will be available approximately two hours after the webcast by dialing 800-585-8367 (U.S.) and +1 416-621-4642 (outside U.S.) and entering a passcode of 93203758. The telephone replay will be available until November 9, 2017.

About ResMed

ResMed (NYSE: RMD, ASX: RMD) changes lives with award-winning medical devices and cutting-edge cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 4 million patients remotely monitored every day. Our 6,000-strong team is committed to creating the world’s best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 120 countries.

Safe harbor statement

Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding ResMed’s projections of future revenue or earnings, expenses, new product development, new product launches and new markets for its products and the integration of acquisitions – are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed’s periodic reports on file with the U.S. Securities & Exchange Commission. ResMed does not undertake to update its forward-looking statements.

– More –

RESMED INC AND SUBSIDIARIES

Condensed Consolidated Statements of Income (Unaudited)

(In thousands, except per share data)

– More –

RESMED INC AND SUBSIDIARIES

Condensed Consolidated Balance Sheets (Unaudited - In thousands)

– More –

RESMED INC AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows (Unaudited - In thousands)

– More –

Reconciliation of Non-GAAP Financial Measures (Unaudited)

(In US$ thousands, except share and per share data)

The measure, “non-GAAP income from operations” is reconciled with GAAP income from operations below:

The measures “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:

ResMed believes that non-GAAP diluted earnings per share is an additional measure of performance investors can use to compare operating results between reporting periods. ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight in evaluating ResMed’s performance from core operations and provides consistent financial reporting. Our use of non-GAAP measures is intended to supplement, and not to replace, our presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.

– End –